Data from two ongoing clinical trials evaluating Plus Therapeutics’ lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM), was presented at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM). The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture.
“The findings presented at EANM indicate the potential for 186RNL in patients diagnosed with leptomeningeal metastases,” said Norman LaFrance, MD, Chief Medical Officer and Senior Vice President at Plus Therapeutics. “Combined with our Phase 1 data in recurrent glioblastoma, these presentations reinforce the tremendous potential of 186RNL as a versatile radiotherapeutic treatment option for multiple CNS cancers.”
The TOP Trials Oral Presentation titled, “Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases (LM) Phase 1 dose escalation Trial [OP-759],” demonstrated:
The Top Rated Oral Presentation (TROP) titled, “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial [OP-542],” reviewed data which indicate that:
Preliminary Safety, Feasibility Data from ReSPECT-LM Clinical Trial Presented at EANM. Appl Rad Oncol.